Frequency Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Woburn MA United States (2015)
Status: Acquired by Korro Bio (2023)

Organization Overview

First Clinical Trial
2017
NCT03300687
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Frequency Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: Frequency Therapeutics (0) Acquired (1)

fx-322 (6 trials)

Drugs in Phase 1 Trials (1)

Key: Frequency Therapeutics (0) Acquired (1)

fx-345 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Noise-Induced (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Hearing Loss, Sudden (Phase 1)

Presbycusis (Phase 1)

Overview

  • Highest Phase: None
  • # of Trials: 7
  • # of Trial APIs: 2